Literature DB >> 31431155

Changes in renal, bone, lipid, and inflammation markers in HIV-1 patients after combination antiretroviral therapy simplification to dolutegravir monotherapy.

Ingeborg Ea Wijting1, Casper Rokx1, Maria C Zillikens2, Sandra Aa Smits2, Theodora Ems de Vries-Sluijs1, Carolina Am Schurink1, Hannelore I Bax1, Marchina E van der Ende1, Eric Cm van Gorp1, Jan L Nouwen1, Annelies Verbon1, Wouter Fw Bierman3, Bart Ja Rijnders1.   

Abstract

Entities:  

Keywords:  Dolutegravir; bone markers; inflammation markers; lipids; renal markers; tenofovir disoproxil fumarate

Mesh：

Substances：

Year:  2019        PMID： 31431155     DOI： 10.1177/0956462419848962

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN： 0956-4624            Impact factor:   1.359


× No keyword cloud information.
  2 in total

1.  Bone Safety of Dolutegravir-Containing Regimens in People Living with HIV: Results from a Real-World Cohort.

Authors:  Paolo Bonfanti; Andrea De Vito; Elena Ricci; Barbara Menzaghi; Giancarlo Orofino; Nicola Squillace; Chiara Molteni; Giuseppe Vittorio De Socio; Elena Salomoni; Benedetto Maurizio Celesia; Chiara Dentone; Valeria Colombo; Giordano Madeddu
Journal:  Infect Drug Resist       Date:  2020-07-14       Impact factor: 4.003

2.  Comparison of Renal Function Biomarkers of Serum Creatinine and Cystatin C in HIV-Infected People on Dolutegravir-Containing Therapy.

Authors:  Lianfeng Lu; Xiaodi Li; Xiaosheng Liu; Yang Han; Zhifeng Qiu; Xiaojing Song; Yanling Li; Xiaoxia Li; Wei Cao; Taisheng Li
Journal:  Infect Drug Resist       Date:  2022-04-08       Impact factor: 4.003
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.